Salarius Pharmaceuticals Stock Trading Halted Pending News
PorAinvest
sábado, 16 de agosto de 2025, 9:54 am ET1 min de lectura
SLRX--
In the recent past, Salarius Pharmaceuticals has been actively working on its reverse stock split, which was announced on August 14, 2025. The company aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement by reducing its outstanding shares from approximately 7.6 million to 509,000 shares. This move is expected to take effect on August 18, 2025 [1].
Additionally, Salarius Pharmaceuticals has been making significant strides in its oncology drug development. The company has reported promising clinical trial results for its LSD1 inhibitor seclidemstat (SP-2577), which is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [2]. The drug has shown supporting evidence in inhibiting LSD1, a validated target in cancer treatment.
Furthermore, Salarius Pharmaceuticals has announced a merger with Decoy Therapeutics, a private preclinical biopharmaceutical company. The merger, announced on January 13, 2025, aims to form a new entity focused on developing peptide conjugate therapeutics for respiratory viruses and cancer. The combined company will leverage Decoy's IMP3ACT™ platform for rapid drug design [3].
The pending news is likely related to these ongoing developments or other significant announcements that Salarius Pharmaceuticals may have in store. Investors are advised to monitor the situation closely and stay updated on any official communications from the company.
References:
[1] https://www.stocktitan.net/news/SLRX/
[2] https://www.stocktitan.net/news/SLRX/
[3] https://www.stocktitan.net/news/SLRX/
Salarius Pharmaceuticals (SLRX) trading has been halted due to pending news. No further information is available at this time.
Salarius Pharmaceuticals (SLRX) has seen its trading halted due to pending news, with no further information available at this time. The stock has been under scrutiny following several significant developments, including a reverse stock split and a merger with Decoy Therapeutics. The halt in trading is a common practice when companies have important news to disclose, allowing investors to digest the information before resuming trading.In the recent past, Salarius Pharmaceuticals has been actively working on its reverse stock split, which was announced on August 14, 2025. The company aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement by reducing its outstanding shares from approximately 7.6 million to 509,000 shares. This move is expected to take effect on August 18, 2025 [1].
Additionally, Salarius Pharmaceuticals has been making significant strides in its oncology drug development. The company has reported promising clinical trial results for its LSD1 inhibitor seclidemstat (SP-2577), which is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) [2]. The drug has shown supporting evidence in inhibiting LSD1, a validated target in cancer treatment.
Furthermore, Salarius Pharmaceuticals has announced a merger with Decoy Therapeutics, a private preclinical biopharmaceutical company. The merger, announced on January 13, 2025, aims to form a new entity focused on developing peptide conjugate therapeutics for respiratory viruses and cancer. The combined company will leverage Decoy's IMP3ACT™ platform for rapid drug design [3].
The pending news is likely related to these ongoing developments or other significant announcements that Salarius Pharmaceuticals may have in store. Investors are advised to monitor the situation closely and stay updated on any official communications from the company.
References:
[1] https://www.stocktitan.net/news/SLRX/
[2] https://www.stocktitan.net/news/SLRX/
[3] https://www.stocktitan.net/news/SLRX/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios